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Introduction: Microdosing is an approach to early drug development where
exploratory pharmacokinetic data are acquired in humans using inherently
safe sub-pharmacologic doses of drug. The first publication of microdose
data was 10 years ago and this review comprehensively explores themicrodose
concept from conception, over the past decade, up until the current date.
Areas covered: The authors define and distinguish the concept of microdos-
ing from similar approaches. The authors review the ability of microdosing
to provide exploratory pharmacokinetics (concentration-time data) but
exclude microdosing using positron emission tomography. The article pro-
vides a comprehensive review of data within the peer-reviewed literature as
well as the latest applications and a look into the future, towards where
microdosing may be headed.
Expert opinion: Evidence so far suggests that microdosing may be a better
predictive tool of human pharmacokinetics than alternative methods and
combinationwith physiologically basedmodellingmay lead tomuchmore reli-
able predictions in the future. The concept has also been applied to drug-
drug interactions, polymorphism and assessing drug concentrations over time
at its site of action. Microdosing may yet have more to offer in unanticipated
directions and provide benefits that have not been fully realised to date.
Keywords: dose linearity, microdosing, pharmacokinetic prediction, pharmacokinetics, Phase 0
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1. Introduction
The concept of microdosing first appeared in the late 1990s as a method of assessing
human pharmacokinetics prior to full Phase I clinical trials [1] and the first data
appeared in the literature in 2003 [2]. Whilst other methods of pharmacokinetic pre-
diction rely on extrapolation of data from in vitro, in silico or animal models, micro-
dosing obtains data directly from the target species -- that is human. Based upon the
adage that “human is the best model for human” microdosing offers an inherently
safe way of obtaining exploratory pharmacokinetic data from humans, primarily
to enable the elimination of drugs from entering costly full development programs
at the earliest possible stage in the clinical studies. This is the theory at least but
how well microdosing has performed against other methods of pharmacokinetic
prediction is partly the subject of this review.
In a human microdose study a sub-pharmacologically active dose of drug is
administered and samples (typically plasma) are collected and analysed for parent
drug or metabolites. Since the very small doses administered are of low toxicological
risk, regulatory agencies allow a microdose to be administered to human subjects
based upon a reduced safety package compared to that required for a full Phase I
clinical trial [3] (that is with no genotoxicology investigations and a single-
dose rodent toxicology study). The cost of a microdose study, including the safety
toxicology assessments, is considerably less than a Phase I study and could be
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conducted in a relatively short period of time (approximately
6 months) [4]. The data from a microdose study are, however,
exploratory and there are questions regarding how well the
data from a sub-pharmacologically active dose might scale to
the higher doses relevant to clinical use (which is discussed
in more detail below).
Despite some accounts that poor pharmacokinetics is no
longer a major contributor to drug attrition [5], pharmaceuti-
cal companies still invest considerable effort in early human
pharmacokinetic prediction [6]. Because human microdosing
studies are performed prior to Phase I, they have become
known as Phase 0 [7] studies (although the regulatory author-
ities never adopted the terminology and prefer to call them
exploratory clinical trials [8]).
Microdosing has caused a lot of debate, and opinion can be
rather polarised [9,10] with some commentators believing that
it has little function in drug development, whilst others seeing
greater benefit. The authors openly declare that they do see
benefit in the technique, in its widest sense and so this review
leans in this direction. Nevertheless, we have attempted to bal-
ance the arguments as far as possible, within the confines of
the space available in a review such as this. The adoption of
microdosing, as with any similar technique, will largely be
driven by the economics. The argument for microdosing is
that if it reduces the frequency that drugs enter full clinical
development that otherwise would have been found to exhibit
poor pharmacokinetics, then significant overall cost savings
will result. Published examination of the economics is very
limited however [11], and so the true cost-savings (or indeed
cost burden) of microdosing is unknown. For this reason,
the economics of microdosing is not discussed here but there
is a real need for an independent and thorough study to
understand what the economic benefits or burdens might be.
1.2 Microdosing and the regulatory guidelines
The first paper to directly address the concept of microdosing
was published 10 years ago [2] but the maximum dose that
defined a microdose was not proposed at that time. The reg-
ulatory authorities followed with a position paper from the
European Medicines Agency 2004 [12], guidelines from the
FDA in 2006 [13], Japan in 2008 [14] and now the current
definitive international guideline in 2009 [8]. A microdose is
defined in all of these regulatory documents as being a dose
of drug that is 1% of the pharmacologically active dose, up
to a maximum of 100 µg. The latest ICH M3 guideline [8],
now universally accepted, allows a microdose to be adminis-
tered to human subjects based on a single-dose toxicity study
(usually in the rat), followed by 14 days observation, using the
intended route of administration (or via the intravenous
route), plus some in vitro target receptor data. The dose
administered in the toxicity study should be 1000 times the
human microdose. The safety data thus obtained can be
used to justify the administration of a maximum of 100 µg
of drug, either as a single dose or as a series of divided doses
to humans (for example, a two-way crossover study of 50 µg
each). The ICH M3 regulatory guideline offers other possible
scenarios such as the administration of up to 500 µg in a max-
imum of five different administrations (a maximum of 100 µg
each with a period of six half-lives between doses), based on a
7-day repeat toxicity study [15] but this review will focus on
the situation where the total dose is limited to 100 µg.
This review covers microdosing used to acquire traditional
concentration-time pharmacokinetic data as opposed to imag-
ing techniques such as positron emission tomography (PET).
PET has been used with microdosing studies [16], and indeed in
one case, traditional concentration-time pharmacokinetic data
were acquired alongside PET images [17]. PET human micro-
dose studies are, however, outside of the current review and
the reader is referred to other publications in this respect [18,19].
2. Definitions
The low dose administered in a human microdose study will
inevitably lead to low plasma-drug concentrations and so sen-
sitive analytical technologies are necessary in order to make the
requisite measurements over an appropriate time. For this rea-
son, particularly for the first microdose studies conducted, the
Article highlights.
. The definition of a microdose should be confined to
situations where a maximum of 1% of the
pharmacologic dose or 100 µg in total is administered to
human subjects and they are not exposed to any higher
level of drug by any other route of administration in the
same study.
. There are currently a total 35 compounds where
microdose and therapeutic dose data have been
compared (oral, intravenous, human and animal). Of the
35 compounds (human and animal), 27 tested orally
showed scalable pharmacokinetics between a microdose
and a therapeutic dose (79%) and 100% of those
tested intravenously.
. Microdosing shows great promise but care has to be
taken when comparing microdosing to alternative
methods as the microdose database is limited and
contains mostly BDDCS class-1 drugs.
. Microdosing has also been applied to the study of
drug-drug interactions, measuring drug concentrations
at the site of action, and metabolic profiling.
. Combination of microdosing with physiologically based
models and similar modelling methods may lead to
improved pharmacokinetic scalability.
. Microdosing is an attractive approach for the study of
new and existing drugs in vulnerable populations
(children, pregnant women, elderly, hepatically and
renally impaired), who are routinely excluded from
clinical trials due to safety concerns.
. Microdose stakeholders (regulatory, industry, academia)
should collaborate to systematically validate
microdosing, including its economics, as a drug
development approach.
This box summarises key points contained in the article.
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drug was labelled with 14C and accelerator mass spectrometry
(AMS) was used as a very sensitive analytical technique, capable
of detecting drug concentrations in the femtogram to attogram
(10-15 -- 10-18 g) range [20,21]. The application of AMS to
microdosing, however, has led to some confusion and it is
worth pausing for a moment to clarify the terminology.
Because of its initial association, microdosing is sometimes
seen as synonymous with AMS. This is, however, incorrect.
Not all studies using AMS are microdose studies and not all
microdose studies utilise AMS. AMS has, for example, been
used in human absorption, distribution metabolism and excre-
tion (ADME) studies for regulatory submission where a thera-
peutic dose is administered containing a very small amount of
14C-compound (typically equivalent to 100 -- 500 nCi) [22].
These types of study have been described as ADME studies
using a ‘microdose’ of 14C-drug [23] but such terminology is
potentially misleading. The proportion of 14C-compound
may be 100 µg or less but the total dose administered is at, or
close to, that intended to be used for therapeutic effect. In a
true microdose study the human subjects are only exposed to
1% of the pharmacologic dose or a maximum of 100 µg,
whichever is lower, irrespective of whether the drug is
14C-labelled or not [24].
Another type of study involving AMS that is often confused
with microdosing is an absolute bioavailability intravenous
tracer study [25]. In this type of study human subjects are
administered a therapeutic dose of drug by an extravascular
route (typically oral) along with a concomitant tracer intrave-
nous administration of 14C-labelled drug [25]. The pharmaco-
kinetics of the oral dose is followed by measuring the
concentration of non-labelled drug in plasma over time
(typically with liquid chromatography-mass spectrometry
(LC-MS)) and the intravenous pharmacokinetics is followed
by measuring the 14C-drug with LC and AMS. (The same
principle can be applied to stable isotope labelling which
was first developed in the 1970s [26].) The 14C isotopic label
in the intravenously administered drug allows the pharmaco-
kinetics of the intravenous dose to be distinguished from that
of the oral dose, thereby obtaining both the oral and intrave-
nous pharmacokinetics from the same subject in a single dos-
ing. The intravenous dose is sometimes referred to as a
‘microdose’, for example [27,28], but this is again misleading as
the underlying pharmacokinetics of the tracer intravenous
dose is very different to a true microdose where the human sub-
jects are only systemically exposed to a maximum of 100 µg
irrespective of the route of administration. In the intravenous
tracer study, there is no question of extrapolating the pharma-
cokinetics from a low ‘microdose’ to a therapeutic dose as the
systemic concentrations of drug are mostly driven by the
absorbed therapeutic dose given orally. In fact the method, first
developed in the 1970s, was primarily aimed at situations where
the value of absolute oral bioavailability obtained from the tradi-
tional intravenous-oral crossover design was flawed by non-
equivalent clearance when plasma concentrations attained from
the oral and intravenous doses were significantly different [25].
In a true microdose study, the drug may be isotopically
labelled but it is not an absolute necessity (see Section 3).
In a tracer study, the ‘tracer intravenous dose’ has to be isoto-
pically labelled to distinguish it from the extravascular dose.
The confusion with microdosing and tracer dosing in this
case arises from the description of the intravenous dose
being < 100 µg and it is perhaps unfortunate that even the
ICH M3 guideline confuses this terminology [8]. An example
of where the terminology has caused confusion can be seen
with the account published by Boddy et al. [29] where oral
doses of 100 mg (13.6 kBq) 14C-imatinib were administered
to cancer patients with subsequent plasma samples analysed
by AMS. The study has been described incorrectly as a micro-
dose Phase 0 study, presumably because of the association
with AMS [30]. In another example, it was claimed that a
microdose of erythromycin exhibited linear pharmacokinetics
when given by the intravenous route [9]. In fact no comparison
can be made in that study as erythromycin was administered
as a 14C intravenous tracer dose along with a therapeutic
oral non-labelled dose, not as a microdose alone [31].
A similar error was made when the pharmacokinetics of nelfi-
navir [9] was declared as non-linear between a microdose and a
therapeutic dose, whereas the drug was administered as an
intravenous tracer, not a microdose [32]. There are numerous
other examples that can be cited where confusion has arisen
between a true microdose study and a tracer study [33]. Such
confusion is understandable given the ambiguous use of ter-
minology in the literature. Other commentators have also
pointed out the confusion in the terminology [10] and so the
current authors would therefore stress the difference between
a microdose study and a tracer study (sometimes referred to
as a micro-tracer study) and hope that the literature of the
future will become more precise. It is also worth pointing
out that although the term ‘microdose’ in its present context
is only about 10 years old, the use of tracer was first coined
by Hevesy (Nobel prize in 1943) where he described “the
use of a radioactive isotope as an indicator or tracer to mark
its inseparable non-radioactive element travelled by tracking
the radioactivity” [34]. Tracer studies, therefore, have a very
long and established pedigree.
3. Analytical methods associated with
microdosing
A microdose is typically administered to four to six healthy
male subjects (although female subjects have been used [31])
followed by the collection of plasma and sometimes excreta
or biopsy samples over time. The samples are analysed for tar-
get analytes such as parent drug or metabolites to ascertain the
pharmacokinetic profile. The low doses administered obvi-
ously demand the use of highly sensitive analytical techniques
in order to measure the plasma drug concentrations over suffi-
cient time. The majority of human microdose studies reported
in the literature have been conducted using 14C-labelled drug
and analysis conducted using the ultrasensitive isotope-ratio
Microdosing and drug development: past, present and future
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technique of AMS although studies have also been performed
using non-labelled drug and sensitive LC-MS [35,36] and the rel-
ative merits of both techniques have been previously dis-
cussed [16]. The choice of analytical technique is largely
driven by the expected plasma-drug concentrations and the
limit of quantification of the analytical method. The sensitivity
of LC-MS assay is highly compound dependent, whilst the sen-
sitivity of an AMS assay depends entirely upon the specific
radioactivity of the analyte and is independent of structure
and matrix effects. It has been estimated that LC-MS assays
would have been adequate for microdosing studies for over
70% of the best-selling drugs worldwide, assuming that a
100 µg dose was administered [36], although in practice at the
time a microdose study would have been conducted the
expected human plasma concentrations may not have been
known with any certainty. In addition, care has to be taken
when comparing the sensitivity of an LC-MS assay developed
over long periods of time to one developed early in the drug
development process, such as would be the case when a micro-
dose study is performed. As a general guide a drug with a vol-
ume of distribution of 300 L administered intravenously to
human volunteers as a 100 µg dose will exhibit a plasma con-
centration of approximately 10 pg/mL after 5 half-lives. Drugs
dosed at 100 µg therefore with expected volumes of distribu-
tion greater than 300 L or orally administered drugs with lim-
ited bioavailability may therefore require assays with greater
than 10 pg/mL sensitivity [37]. Some LC-MS assays can achieve
these levels of sensitivity but by no means all [16]. Of course, if
the microdose is < 100 µg, more sensitive analytical assays are
required. If AMS is used as the analytical method, then the
drug has to be isotopically labelled with 14C. Given that the
microdose study is performed at a relatively early stage of
drug development, the likelihood is that a 14C-drug had not
been synthesised previously. This means, therefore, that a
14C-drug synthesis is likely to be necessary for the microdose
study, which adds cost and time. On the other hand, inclusion
of 14C in the drug can have advantages in terms of determining
the metabolic profile of the drug, albeit at a low dose [38] and
this is discussed further below (Section 4.2.5).
Despite some limitations on the assay sensitivity, there is a
growing use of LC-MS in microdosing as it can offer certain
advantages. For example, the administration of mixtures of
compounds as a microdose cassette has the advantage that sev-
eral candidate drugs could be tested in a single dosing. This
approach has been investigated using LC-MS [39] and LC
and AMS [40]. Unlike LC-MS, AMS does not reveal any struc-
tural information and cannot resolve compounds based on
molecular weight. Resolution of compounds for AMS analysis
relies entirely upon the chromatographic separation, which
may demand, for example, two-dimensional HPLC, to be
confident of complete separation of a target analyte from a
mixture where other unknown interfering compounds could
be present [40]. In addition, AMS analysis involves a degree
of sample processing to form graphite after chromatographic
separation, which also demands the accurate addition of an
isotopic dilutor [41]. This coupled to the limited number of
suitable AMS instruments, with GlaxoSmithKline being the
only pharmaceutical company currently with its own AMS
facility [42] and LC-MS can often be a winning pragmatic
choice.
4. The utility of microdosing
The original concept of microdosing was to provide pharma-
cokinetic data as early as possible in humans, which could be
used to assess the pharmacokinetics at higher therapeutic
doses. The technique has moved on from there insomuch as
it has been extended to assess the magnitude of potential
drug-drug interactions, early indications of the metabolic pro-
file of the drug as well as in the study of polymorphisms and
transporters. In addition, microdosing can be used to assess if
the drug is reaching its intended target tissues in human sub-
jects. Each of these applications of microdosing, along with
the literature, will be explored below.
4.1 Exploratory pharmacokinetic data
The literature-reporting studies where microdose pharmaco-
kinetics can be compared to those observed at the therapeutic
dose are a mixture of study designs, species and analytical
methods. The microdose literature is also limited because of
confidentiality issues at the early stage of development (for
example [43]). In addition, for drugs in development, micro-
dose studies can be performed before the drug might be
administered at therapeutic doses and so it can be some
time before the therapeutic data are published. There are
therefore a number of accounts of microdosing in the
literature where a therapeutic dose of drug has not yet been
given [35,44,45]. A comprehensive summary of the peer-
reviewed literature comparing human microdose with
therapeutic dose pharmacokinetics is shown in Table 1.
Some testing of the microdose concept has also been con-
ducted in animal models and these data are summarised
in Table 2. The last review by one of the current authors
(GL) that appeared in this journal was in 2008, where
18 drugs were reported [46]. In the current review, 35 separate
drugs have now been examined (total of oral, intravenous,
human and animal data). A further breakdown of the data is
provided in Table 3, showing the number of human micro-
dose studies against each Biopharmaceutics Drug Disposition
Classification System (BDDCS) class that showed linear or
non-linear pharmacokinetics for oral and intravenous dosing.
Taking all the data into account, 79% of drugs so far tested
between a microdose and a therapeutic dose have demon-
strated scalable pharmacokinetics within a factor of two-
fold for any given parameter. The two-fold factor is discussed
further below, but if this is widened to three-fold, then 91%
of drugs so far tested are within this range. For oral adminis-
tration, approximately 62% of the drugs tested showed phar-
macokinetics scalable within a factor of 2 and 85% within a
three-fold range. It should be noted that the three drugs
G. Lappin et al.
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considered non-scalable outside the three-fold range are classi-
fied in this way as the microdose did not predict the shape of
the drug-concentration-time curve well for the oral dose
(see Table 3). For intravenous administration, the pharmacoki-
netics for all drugs so far examined have been scalable (i.e., a
100% success rate).
There appear to be two main reasons, so far identified, that
explain pharmacokinetic non-linearity when it occurs with
oral dosing. The first is typified by warfarin, a low volume
of distribution drug with a high affinity for a low-capacity
binding site (hepatic vitamin K epoxide reductase). The kinet-
ics observed at the microdose is classical for target-
mediated disposition, where the plasma concentrations
decrease rapidly as the drug attaches to its binding site. At
higher doses, as the binding site becomes saturated, then the
plasma concentrations are proportionally higher and the rapid
decrease in concentration at the early time points is no longer
observed. The phenomenon has been observed in human
microdosing [31] as well as in studies in the rat [47]. This type
of disposition kinetics is also typical for monoclonal antibod-
ies, which are well known for exhibiting non-linear pharma-
cokinetics. Microdosing for the purpose of predicting drug
pharmacokinetics is therefore probably ruled out for thera-
peutic proteins that exhibit target-mediated disposition. In
addition, although the pharmacokinetics of warfarin has not
been compared between a microdose and a therapeutic dose
via the intravenous route, it is a reasonable assumption that
the intravenous pharmacokinetics in this case would be non-
linear. Very few small molecules exhibit target-mediated dis-
position and therefore non-linearity due to this property is
unlikely to arise very often.
The other major cause of non-linearity arises when the
therapeutic dose saturates some enzyme or transporter system.
Propafenone typifies such a drug, where bioavailability
increases disproportionally to dose, as CYP 2D6 become
saturated as the dose increases, thereby reducing the effect of
first-pass metabolism [31]. In most cases failure of the oral
microdose to predict the pharmacokinetics of therapeutic
doses appears to be saturation in the gut wall [10,48]. The ques-
tion under these circumstances is, will the microdose data be
close enough to the therapeutic dose data to enable an appro-
priate choice to be made on the continued development of the
drug? In the case of propafenone, the absolute oral bioavail-
ability obtained from the microdose study was 5.8% and for
the therapeutic dose it was 13% [48]. Although the compara-
tive values were just outside the two-fold threshold, the overall
conclusion that the drug exhibited limited bioavailability was
nevertheless predicted from the microdose. It is important to
interpret microdose data in the context that it is exploratory
and also how it compares with other predictive methods.
It has, for example, been claimed that diazepam exhibited
non-linear pharmacokinetics between a microdose and thera-
peutic dose because of a 0.3-fold difference in volume of
distribution [9]. In reality, however, attaining this degree of
precision is likely to be an impractical standard for any
method of pharmacokinetic prediction. Diazepam is in fact
a good example of where microdosing could be useful, as its
clearance is significantly over-predicted by allometric scaling.
Diazepam, along with certain other drugs such as warfarin,
reboxetine and tamsulosin, are classed as having “a large verti-
cal allometry” where clearance is over-predicted, by over
3000% in the case of diazepam [49]. These magnitudes of
errors have not been seen thus far with microdosing, even in
the case of warfarin where target-mediated disposition is a
demonstrated mechanism on non-linearity.
Table 3. Summary of microdose outcomes for human
studies categorised against BDDCS class.
BDDCS class PK scalability
within two-fold
PK scalability greater
than two-fold
Oral administration
1 Midazolam
Paracetamol
(acetaminophen)
Phenobarbital
Diphenhydramine
Nicardapine
Caffeine
Enalapril
Quinine
Zidovudine
Sumatriptan
(within three-fold)
2 Tolbutamide
Losartan
Raltegravir
Warfarin (shape
poorly predicted)
Propafenone (within
three-fold)
Telmisartan (shape
poorly predicted)
3 Fexofenadine
Clarithromycin
Tenofovir
Atenolol
Metformin
Celiprolol (shape
poorly predicted)
Unknown ZK-253
IDX899
A1A adrenoceptor
antagonist
Total 20 5 within two-fold and
3 within three-fold
Intravenous administration
1 Diazepam
Midazolam
Sumatriptan
Paracetamol (acetaminophen)
Diphenhydramine
Verapamil
2 Propafenone
Raltegravir
3 Fexofenadine
Clarithromycin
Unknown ZK253
IDX899
Total 12 0
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Attempts have been made to identify classes of drug based
upon physiochemical or pharmacokinetic properties, which
are better- or worse suited to microdosing [46] but no conclu-
sions have been drawn. Tables 1 -- 3 in the current review
examine pharmacokinetic scalability in relation to the
BDDCS class for the drug. Drugs in BDDCS class 2 (high
permeability, low solubility compounds where efflux trans-
porter effects predominate in the gut) might be particularly
challenging for microdosing as absorption may be governed
by solubility. (BDDCS, as proposed by Benet et al. [50], is
considered a more appropriate classification system in the cur-
rent context as the more widely used Biopharmaceuticals
Classification System considers the magnitude of absorption
whereas BDDCS also accounts for the rate.) Nevertheless,
there are six BDDCS class-2 drugs represented in Tables 1
and 2 and the microdose data get very close to being scalable
to the therapeutic dose with four of those. From the current
data, however, it is hard to draw any conclusions based on
drug classification systems [10] as indeed it was based upon a
range of physiochemical and metabolic properties reported
in 2008 [46].
When assessing the utility of microdosing it is important to
keep conclusions in the context of other methods of pharma-
cokinetic prediction. The three most commonly used
‘traditional’ methods are allometry, physiologically based
pharmacokinetic (PB-PK) modelling and in vitro-in vivo
extrapolation (IVIVE). These methods rely on the input of
the drug’s physiochemical properties and its behaviour
in vitro and in animal species into mathematical models in
order to output pharmacokinetic predictions in humans.
The models rely on an understanding of the complex mecha-
nisms of drug metabolism or are largely empirical [51]. (One is
reminded of the statistician George Box, when he said, “All
models are wrong, but some are useful”.) The data from a
microdose study, however, are largely the end result in itself
and only require dose-normalisation to provide the output
(although the prospect of including some pharmacokinetic
modelling with microdose data is emerging -- see later in
this section). The question that then remains is, will the phar-
macokinetics observed with a microdose reflect that at a ther-
apeutic dose sufficiently well for appropriate decisions to be
made in the drug’s development? When making such assess-
ments on the performance of microdosing it is important to
place any conclusions in the context of the above-mentioned
mathematically based models and to consider how microdos-
ing can be best used alongside these models to obtain the most
reliable data.
At the time of the first publication in 2003 there were vir-
tually no data to support the hypothesis that microdosing data
would scale sufficiently well to the therapeutic dose. Nowa-
days there is a database that overall looks very promising
(see Tables 1 and 2) but as will be explained below, some cau-
tion has to be taken when comparing the microdose database
with the performance of pharmacokinetic prediction from the
methods that involve mathematical models. It is very difficult
to compare exactly like with like as the microdose database is
relatively small compared to the many hundreds or thousands
of papers on pharmacokinetic modelling. Comparisons are
complicated by the fact that the microdose database consists
of many older drugs (BDDCS class-1 dominates), whereas
many of the more modern compounds are in BDDCS class-
2. In addition, it somewhat depends on how the data are com-
pared. A commonly used criterion in allometry is to accept
that the pharmacokinetics is predictive if they are within a fac-
tor of 2 [52]. This is a very convenient comparator and it is also
used in this review in respect to microdosing (although three-
fold has been used in places) but its limitations should be
understood. Normally, the metric evaluated is a PK parameter
such as CL, V or oral bioavailability, although arguably shape
of profile is often equally important to predict [10]. Further-
more, caution should be exercised in the application of a
defined tolerance (such as two-fold) given that most pharma-
cokinetic parameters are bounded. For example, percent bio-
availability lies between 0 and 100 and organ clearance
between 0 and organ blood flow. If, for arguments sake, the
reference value for bioavailability is 15%, application of a
two-fold tolerance seems reasonable but if the reference value
is 70% then this application would clearly be inappropriate.
On the other hand, if the true bioavailability was, say, 1%,
and a microdose study predicted 5%, then the result would
still be valuable in terms of drug selection although well out-
side of the two-fold criterion. The pharmacokinetic tolerance
is also highly dependent upon the therapeutic window, which
is drug-specific.
A recent study sponsored by the Pharmaceutical Research
and Manufacturers of America examined the performance of
allometry, PB-PK and IVIVE as predictors of human pharma-
cokinetics. A total of 89 drugs administered by the oral route
and 19 by the intravenous route were assessed and the best
methods could only predict events after oral administration
in the order of 45% of the time [6,53-57]. It is particularly poi-
gnant that only 21% of the drugs examined were ever admin-
istered to humans by the intravenous route, and this will be
discussed again in Section 4.2.4.
4.2 Emerging uses of microdosing
Although the emphasis has been on pharmacokinetic predic-
tion there are other applications of microdosing that are
emerging, which are discussed below. In order for pharmaco-
kinetic prediction to improve, it is important to understand
the underlying mechanisms responsible for non-linearity,
such as rate-limiting steps in hepatic clearance [58]. Attempts
have been made to account for the saturability of enzyme
and transporter systems in predicting non-linear pharmacoki-
netics in microdose studies. For example, the relationship
between dose-normalised AUC and dose/Km value has been
termed the linearity index (LIN). Substrates with a small
LIN tend to exhibit linear pharmacokinetics [59]. The combi-
nation of pharmacokinetic models and microdosing, particu-
larly in cases where there are significant doubts over the inputs
G. Lappin et al.
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to the models, may prove to be a powerful tool of the future.
Microdosing and methods of PK modelling are not, therefore,
necessarily mutually exclusive. In particular, this might apply
to the estimate of clearance in humans (discussed in Section
4.2.4) [10].
4.2.1 Drug-drug interactions and polymorphism
Potential drug-drug interactions have been investigated dur-
ing a human microdose study [40]. The principle here is that
the magnitude of such interactions can be difficult to predict
prior to clinical studies. The limited safety toxicology required
to conduct a microdose study (see Section 1) allows a drug-
drug interaction study to be performed in humans before
the drug enters Phase I. The pharmacokinetics of a develop-
ment drug administered as a microdose before and after
administration of pharmacological active doses of a suitable
inducer or inhibitor of a chosen enzyme or transporter (keto-
conazole and fluvoxamine in the case of [40]) is compared. The
scenario is only applicable when the development drug is a
potential victim of a drug-drug interaction and the marketed
drug is the perpetrator. Questions as to what drug-drug inter-
actions might be caused by the development drug itself have
to be conducted after pharmacological active doses can be
administered (post Phase I). Similarly, microdosing has been
used to study food-drug interactions [60] and microdose
probes have also been used to examine polymorphisms associ-
ated with drug transporters [61]. In the case of polymorphism
studies, microdosing was applied principally from a safety
perspective, where the sub-pharmacologic doses represented
a very low risk in a genetically diverse population.
4.2.2 Site of action
A drug that exhibits an appropriate concentration at its site of
action for a required period of time, but is also present off-
target (e.g., in the plasma) to only a limited extent, will stand
the best chance of having the necessary balance between high
efficacy and low toxicity. Although plasma samples are rou-
tinely taken in pharmacokinetic studies, few studies attempt
to sample tissues in order to measure drug concentrations.
Tissue sampling is of course difficult in humans for obvious
ethical reasons. Nevertheless, certain tissue samples have
been obtained such as gastrointestinal tract during sur-
gery [62,63] and lung samples by bronchoalveolar lavage and
bronchial mucosal biopsy [64]. In the latter case, the use of
14C-drug and AMS allowed for alveolar macrophages to be
profiled to determine the concentrations of active parent
drug versus metabolites.
Zidovudine and tenofovir require intracellular phosphory-
lation for antiviral activity. It is thought that the lack of intra-
cellular phosphorylation might explain the lack of efficacy of
certain nucleotide analogues but this is often only discovered
once the drug is in full development [65]. The prospect of
screening anti-HIV drugs in humans using microdosing prior
to Phase I clinical trials is therefore an attractive prospect.
Measurement of the parent drug in plasma does not correlate
well with efficacy, and assays for the phosphorylated drug in
peripheral blood mononuclear cells (PBMCs) are required.
In a series of studies, the degree of phosphorylation of zidovu-
dine and tenofovir was demonstrated in human microdose
studies using 14C-drug and highly sensitive AMS [66-68]. Inter-
estingly, one paper indicated that intracellular zidovudine
concentrations showed linear pharmacokinetics between a
microdose and a therapeutic dose [67], whilst the other paper
reported non-linear intracellular pharmacokinetics [66]. Both
papers reported linear plasma pharmacokinetics. Where teno-
fovir was studied, the pharmacokinetics was linear in plasma
and intracellular concentrations.
In a series of recent studies the extent of DNA methylation
occurring in brain tumours in cancer patients was investi-
gated. Temozolomide is an alkylating agent shown to have
antitumor activity in patients with recurrent and refractory
high-grade glioma and melanoma in Phase I and II trials [69].
Recent clinical evidence suggests that glioblastoma multi-
forme is a heterogeneous disease with 50% of the population
responding poorly to temozolomide treatment [70]. To date, it
has not been readily possible to measure temozolomide-
induced tissue endpoints in a clinical setting. Recent clinical
studies have demonstrated the sensitivity of AMS in the
quantitation of 14C-tamoxifen [71] and 14C-PhIP (2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine) tumour uptake
and DNA binding [63]. A recent clinical trial in glioblastoma
multiforme patients is using AMS to quantify tumour uptake
and temozlomide-induced DNAmethylation after the admin-
istration of oral microdoses (50 µg) of 14C-temozlomide. The
aim of the study was to identify potential markers of efficacy
based on a tracer dose of the therapeutic agent with an ulti-
mate goal of developing personalised approaches to therapy
in individual patients (Ali Arjomand, Acciumbiosceince,
personal communication).
4.2.3 Vulnerable populations
The inherent toxicological low risk of a microdose allows
pharmacokinetic studies to be performed in populations
where higher doses are difficult to administer. Microdose
studies have, for example, been performed in paediatric pop-
ulations [72]. The authors are aware of a paediatric microdose
study being run in the European Community but no data
have yet been published.
4.2.4 Intravenous data
It remains the case that only few drugs intended for oral
administration are ever administered to humans via the intra-
venous route. Yet, intravenous data can be invaluable in the
development of the drug, as the fundamental pharmacokinetic
parameters of clearance and volume of distribution are attained.
Whilst volume of distribution tends to be predicted from
allometry [53], the reliable prediction of clearance remains much
more of a challenge [56]. Many of the pharmacokinetic non-
linearity observed in microdosing but intravenous microdosing
currently has a 100% record in predictability (Tables 1 and 3),
Microdosing and drug development: past, present and future
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excluding drugs that display target-mediated disposition. By
incorporating an intravenous microdose study into pharmacoki-
netic simulations, reliable values for drug clearance in humans
could be included, thereby generating much better overall predic-
tions. In a case study, a development compound, PF-4776548,
was quickly terminated based on a combination of microdose
and physiologically based pharmacokinetic studies [73]. Another
compound, PF-184298, was selected for development, mitigat-
ing risks due to oral exposure and metabolism by CYP2D6.
The authors were cautious in their conclusions however, and
pointed out that the alternative of accepting the risk and proceed-
ing to Phase I is always a consideration in terms of time and cost
for any particular programme.
4.2.5 Metabolic profiling
To obtain preliminary data on the metabolism of a candidate,
drug samples from microdose studies have been metabolically
profiled [38]. Although the profiles were obtained from a phar-
macologically inactive dose, they were used to gauge the
potential for the presence of human metabolites being dispro-
portional to those seen in the toxicology species as defined in
the regulatory guidelines [8,74]. In this case, the drug was
14C-labelled in order to quantitatively obtain the profile by
AMS analysis.
5. Expert opinion
The fundamental strengths of microdosing -- improved safety,
reduced cost, and time to developmental decisions -- are likely
to get only stronger. The most important order of business for
the microdosing field is to understand the very modest utilisa-
tion of microdosing by drug developers and address any defi-
ciencies or concerns methodologically and comprehensively.
A systematic survey of industry, academia and regulators
would hopefully identify the challenges and the ways to
address them. Microdosing studies and the approach in gen-
eral may need to undergo systematic validation in large-scale,
government-sponsored trials for universal adoption to take
place. In addition, the true economics of the technique versus
other methods needs to be properly addressed. Since the main
benefit of microdosing to developers would be in elimination
of unsuccessful candidates (successful candidates would have
to go through the full developmental path), clarification of
microdosing impact on the rest of the pipeline needs to be
made. Exploration of the utility of microdosing in vulnerable
populations will likely become attractive with regulatory and
societal pressures increasing in favour of equity of science
and therapeutic development. Since most exclusions in drug
development are due to safety concerns (pregnant women,
children, elderly, hepatically and renally impaired), microdos-
ing studies are optimally poised to provide valuable data.
Microdosing has reached its first decade and in many ways
it has failed to deliver the fervour of expectation that accom-
panied the initial concept [75]. Nevertheless, the authors
believe that it does have a place in drug development and
the data support the role of microdosing in drug development
and it may contribute human data to a phase of development
where the majority of decision-making is currently based on
non-human data. Combination of microdosing and model-
ling may lead to much more reliable predictions in the future.
The concept has been widened from a purely pharmacoki-
netic predictive method towards addressing other questions,
such as drug-drug interactions, polymorphism and looking
at whether a drug is likely to reach its site of action. Microdos-
ing may yet have more to offer in unanticipated directions
and provide benefits that have not been fully realised to date.
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